VNRXVolitionRx Limited

Revenue flat as cost cuts narrowed losses and cash strengthened.

Moby summary of VolitionRx Limited's Q2 2026 earnings call

With an upside potential of 1451.32%, VolitionRx Limited (NYSEAMERICAN:VNRX) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 15, Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx Limited (NYSEAMERICAN:VNRX), stated that the company made substantial progress across multiple product platforms during the first quarter and following quarter-end […]

VolitionRX Ltd (VNRX) reports a 300% revenue increase and expands its global network, despite rising expenses and ongoing commercialization challenges.

Moby summary of VolitionRx Limited's Q1 2026 earnings call

VolitionRX Ltd (VNRX) reports a 133% year-on-year revenue growth and significant partnerships, despite ongoing financial challenges and unpredictable revenue streams.

Moby summary of VolitionRx Limited's Q4 2025 earnings call

VolitionRx (VNRX) announces the completion of all validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories. Volition’s supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q Vet Cancer Test throughout its network of central reference laboratories in Japan. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data

VolitionRX Ltd (VNRX) reports a 32% revenue increase and strategic agreements, while navigating market unpredictability and capital challenges.